ワクチン・医薬品の世界市場への新型コロナウイルス感染症 (Covid-19) の影響：将来予測 (2025年まで)
COVID-19 Impact on Vaccines & Drugs Market - Global Forecast to 2025
|出版日||ページ情報||英文 67 Pages
|ワクチン・医薬品の世界市場への新型コロナウイルス感染症 (Covid-19) の影響：将来予測 (2025年まで) COVID-19 Impact on Vaccines & Drugs Market - Global Forecast to 2025|
|出版日: 2020年05月04日||ページ情報: 英文 67 Pages||
世界の新型コロナウイルス感染症 (Covid-19) ワクチンの市場規模は、2022年には22億7300万米ドル、2025年には14億0100万米ドルに達する、と予測されています。また、Covid-19の治療薬の市場規模は、2020年には1億6500万米ドル、2025年には200万米ドルに達する見通しです。Covid-19の場合、コンパッショネート・ユース (未承認薬の例外的・人道的利用) や、他の感染症 (SARS、MERS、H1N1など) の治療で用いられている回復者由来血清療法などの代替療法が、現在利用可能な治療手段となっています。また、世界各国の政府・企業の協力が円滑に進めば、治療薬の開発や市場成長が促進されると期待されています。ただし、集団免疫や、ワクチン・治療薬の有効性の不確実さといった諸要素が、市場成長の妨げとなる可能性もあります。
当レポートでは、新型コロナウイルス感染症 (Covid-19) 向けワクチン・治療薬の市場の将来展望について分析し、現在有力紙されている治療法や今後の開発・治験の可能性、将来 (承認後) の市場規模の動向見通し、市場の背景事情、大手企業の開発・販売体制、といった情報を取りまとめてお届けいたします。
"The global COVID 19 vaccines market is projected to grow at a CAGR of -14.9% during the forecast period."
The global COVID-19 vaccines market is projected to reach USD 1,401 million by 2025 from USD 2,273 million in 2022, at a CAGR of -14.9% during the forecast period. The growth of the global COVID-19 vaccines market is majorly attributed to the increasing number of people infected with COVID-19 and growing funding for vaccine development.
The global COVID-19 drugs market is projected to reach USD 2 million by 2025 from USD 165 million in 2020, at a CAGR of -57.8% during the forecast period. The growth of COVID-19 drugs market is attributed primarily to use of repurposed drugs for compassionate use and the emergence of alternative therapies such as convalescent plasma therapy which were used earlier for treating epidemic diseases such as SARS, MERS, and H1N1. Furthermore, collaborations between global organizations and governments of various nations to promote the supply of essential drugs and medical supplies will fuel market growth. However, factors such as herd immunity, and uncertainty over the efficacy of vaccines and drugs are expected to hinder the market growth.
Currently, the R&D landscape for COVID-19 vaccines includes 115 vaccine candidates.
The most advanced candidates that have recently moved into clinical development are:
Incentives are needed to engage manufacturers for the large-scale capacity to guarantee sufficient production of SARS-CoV-2 vaccines. In line with this, various global organizations have come forward to expedite the process, such as Gavi, CEPI, and WHO. However, considering the pandemic scenario of COVID-19, much stronger initiatives are required.
In April 2020, the Bill and Melinda Gates Foundation plans to help fund factories for seven promising vaccines, even before seeing conclusive data. The foundation aims to help scale up manufacturing during testing, rather than after the vaccines have passed the trials.
Besides the most promising Moderna program, several other big pharma companies are involved in COVID-19 vaccine work. Johnson & Johnson has pledged a manufacturing scale-up to 1 billion doses for its federally partnered program. Meanwhile, Sanofi has two partnerships underway-one with the federal government and another with Translate Bio.
While global drug makers are pouring massive resources into developing targeted therapies and vaccines, contract development and manufacturing organizations (CDMOs) are finding ways to ramp up the production of vaccines. In line with this, a new CDMO from Belgium's Univercells is offering its expertise to help drug makers scale up their manufacturing.
Pfizer and BioNTech have laid out plans for manufacturing their candidates for trials and producing millions of doses if trials succeed. The companies expect to have millions of doses of a COVID-19 vaccine ready to go by year-end if the companies begin human testing as planned by late April. Pfizer and BioNTech are hoping to advance multiple mRNA vaccine candidates.
Currently, around 155 molecules are under clinical investigation, and approximately 45 molecules are under preclinical development to be targeted against COVID-19. In this list, four promising drugs have been repurposed for use against COVID-19.
Researchers and physicians in several countries are focusing on various other existing drugs to examine their potential to treat COVID-19. Chinese authorities, which have been dealing with the virus longer, are recommending Arbidol (umifenovir), which has not been approved in Western countries, as well as old antivirals ribavirin and interferon-alpha. Similarly, Avigan (favipiravir) by Fujifilm has shown promise in the treatment of COVID-19.
As the maximum number of molecules are repurposed drugs that are already approved for other infections and inflammatory diseases, higher stages of development (namely phase 2 trials) hold the largest share. China, along with other Asian countries, holds the largest share of the number of clinical trials being conducted, followed by Europe and the US. Small molecules hold the largest share, followed by monoclonal antibodies and plasma and cell therapy.
AI-powered technologies are making the drug discovery process more efficient and substantially improve success rates at the early stages of drug development. Artificial intelligence algorithms ingest and analyze a vast amount of information and can identify potential drug candidates in lesser time. Such factors will expedite the drug development process.
A breakdown of the primary participants referred to for this report is provided below:
Some of the major players in the COVID-19 vaccines market include: Pfizer Inc. (US), Johnson & Johnson Services, Inc (US), GlaxoSmithKline plc. (UK), Sanofi (France) Serum Institute of India (India), among others. Major players in the COVID-19 drugs market include Gilead Sciences, Inc. (US), Sanofi (France), F. Hoffmann-La Roche Ltd (Switzerland), Merck KGaA (Germany), and Janssen Pharmaceuticals, Inc. (Belgium), among others.
This report describes and studies the global COVID-19 vaccines and drugs market, current pipeline of vaccines and drugs by phase by companies, competitive landscape, a view point on COVID-19 pipeline, the impact of COVID-19 on other vaccines and drugs in the portfolio/other under development vaccines and drugs, macroeconomic indicators (drivers, restraints, new opportunities), post-COVID-19 approval scenario, challenges in approval/production/supply, strategies to overcome challenges, historical examples (SARS, MERS, Ebola, H1N1), new strategies, strategies to ramp up production at pandemic level, historical examples, and new strategies.
The report can help established firms as well as new entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them garner a greater share. Firms purchasing the report could use one, or a combination of the below mentioned five strategies.
This report provides insights into the following pointers: